You are here

Home » Content

PREVALENCE OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN A TERTIARY CARE HOSPITAL AND SIGNIFICANCE OF LINCOSAMIDE SUSCEPTIBILITY IN MACROLIDE RESISTANT MRSA.

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Context: Methicillin resistant Staphylococcus aureus (MRSA), specifically multiple drug resistant MRSA, are a real threat to the clinician and therapeutic option for these isolates has to be worked out. Objective: The objective of the present study was to assess the prevalence of MRSA in our hospital and further to identify inducible resistance to macrolides (erythromycin) among these MRSA, for therapeutic purpose. Setting and Design: This study was conducted over a period of three years. The clinical samples received from the patients admitted in various ICU’s and wards of Dayan and Medical College & Hospital, Ludhiana, were included in the study. Material and Method: MRSA were detected using 1 μg disc of oxacallin. Two hundred thirty five MRSA which were erythromycin (macrolide) non susceptible but clindamycin susceptible, were tested using 15 mm disc approximation test (D-test) to evaluate erythromycin inducible (ermmediated) and non-inducible (msrA mediated) resistance. Results: prevalence of MRSA was found to be Out of 235 MRSA tested using D test, 51/235 (21.8%) showed negative D test and resistant to erythromycin in these isolate may be mediated by msrA genes. Conclusion: MRSA isolates with negative D-test will not develop resistance during the treatment with lincosamides. Patients with infection caused by multiple drug resistance MRSA with msrA genes may be treated with lincosamides without any fear of developing resistance and clindamycin may be kept as a reserve drug in severe MRSA infections or in cases where the patient is known to have hypersensitivity to β-lactam drugs, depending upon the results of the D-test.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-prevalence-methicillin-resistant-staphylococcus-aureus-mrsa-tertiary-care-hospital-and-significance-lincosamide-susceptibility-macrolide-resistant-mrsa.pdf
  • 5
294
300
  • English

REFERENCES

References: 

1. Craven DE, Kunches LM, Lichtenberg DA,
Kollisch NR, Barry MA, Heeren TC et al.
Nosocomial infections and fatality in
medical and surgical intensive care unit
patients. Achieves of Internal Medicine
1988;148:1161-8.
2. Gross PA, Nen HC, Aswapokee P,
VasnAntewerpen C and Aswapokee N.
Deaths from nosocomial infections:
Experience in a university hospital and
community hospital. TheAmerican Journal
of Medecine.1980; 68:219-23.
3. Rai SK, Tuladhar NR and Shreshtha HG.
Methicillin resistant Staphylococcus aureus
in a tertiary care centre, Nepal. Indian
Journal of Medical
Microbiology.1990;8:108–9.
4. Lacey RW. Multi resitantStaphylococcus
aureus – a suitable case for activity? The
Journal of hospital infection. 1987; 9: 103–5
5. Callopy BT, Dalton M, Wright C, Mullany
C. Comparison of clinical significance of
methicillin resistant and methicillin
sensitive Staphylococcus aureus.
TheMedical Journal of Australia.1984;20:
709-13
6. Boyce JM. MRSA in hospital and long
term care facilities. Microbiology,
epidemiology and prevention measures.
Infection Control and HospEpidemiol.1992;
13: 725–37.
7. Kamat M, Vagarali MA, Karadesai SG.
Inducible clindamycin resistance in
Staphylococci: Should clinicians and
microbiologists be concerned?. J SciSoc
2012;39:7-9
8. Goyal R, Singh NP, Manchanda V and
Mathur M. Detection of clindamycin
susceptibility in macrolide resistant
phenotypes of Staphylococcus aureus.
Indian Journal of Medical Microbiology
2004; 22: 251–4.
9. Siberry GK, Tekle T, Carrol K and Dick J.
Failure of Clindamycin treatment of MRSA
exposing inducible clindamycin resistant invitro.
Clinical Infectious Disease. 2003;37:
1257-60.
10. Barrow GI, Feltham RKA, editors. Cowan
ST and Steel KJ. Manual for identification of
Medical Bacteria. 3rd ed. Cambridge:
Cambridge University Press: 1993.p. 331.
11. Performance standards for antimicrobial
disc susceptibility tests; Approved standard.
CLSI 2006 M2-A9, 26; 1
12. McGowan JE Jr. Antimicrobial resistance
in hospital organisms and its relation to
antibiotic use. Reviews of Infectious Dieases
1983: 5:1033-48
13. Weinstein RA and Kabins SA. Strategies
for prevention and control of multiple drug
resistance nosocomial infections. The
American Journal of Medicine 1981;70:449-
54
14. Centres for Disease Ccontrol and
Preventon. Reduced susceptibility of
Research Article CODEN: IJPRNK ISSN: 2277-8713
Rama Gupta, IJPRBS, 2013; Volume 2(5):294-300 IJPRBS
Available Online at www.ijprbs.com
300
Staphylococcus aureus to vancomycin-
Japan. 1996. MMWR 1997; 46: 624
15. Steward CD, Roney PM, Morrell AK, et
al. Testing for induction of clindamycin
resistance in erythromycin resistant isolates
of S.aureus. Journal of Clinical Microbioogy
2005; 43: 1716-21.
16. Patel M, Waites KB, Moser SA, Cloud GA
and Hoesley CJ (2006) Prevalence of
inducible clindamycin resistance among
community and hospital associated
Staphylococcus aureus isolates. Journal of
ClinicalMicrobioogy2006;44: 2481-4.
17. Woods CR (2009) Macrolide-Inducible
Resistance to Clindamycin and the D-Test.
Pediatr Infect Dis J 2009;28: 1115–8.
18. PrabhuK, RaoS and RaoV (2011)
Inducible clindamycin resistance
in Staphylococcus aureus isolated from
clinical samples .J Lab Physcian 2011; 3(1) :
25-27.

Thank you for copying data from http://www.arastirmax.com